Format

Send to

Choose Destination
Lupus. 2010 Apr;19(4):419-23. doi: 10.1177/0961203309360541.

Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort.

Author information

1
Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland 21205, USA. mpetri@jhmi.edu

Abstract

Anti-phospholipid antibodies are common in patients in the Hopkins' Lupus Cohort: 47% have anti-cardiolipin, 32.5% anti-beta(2)-glycoprotein I and 26% lupus anticoagulant (by dRVVT confirmatory testing). Systemic lupus erythematosus patients with the lupus anticoagulant at baseline have a 50% chance of a deep venous thrombosis/pulmonary embolus in the next 20 years. Anti-phospholipid antibodies differ in their association with thrombosis: the lupus anticoagulant is most strongly associated with arterial and venous thrombosis and is the only anti-phospholipid antibody associated with myocardial infarction. Anti-phospholipid antibodies are not associated with atherosclerosis.

PMID:
20353980
DOI:
10.1177/0961203309360541
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center